The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | An overview of the current landscape of CAR T-cell therapy in myeloma
Susan Bal, MD, University of Alabama at Birmingham, Birmingham, AL, provides insight into her talk on redefining the treatment of multiple myeloma (MM) with CAR T-cell therapy, providing a comprehensive overview of the current landscape of this transformative therapeutic option. Dr Bal mentions some key clinical trials that led to the approval of CAR-T products for myeloma and highlights trials investigating these products in earlier lines of therapy. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
